This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of gallbladder, excluding all cancers (controls excluding all cancers)
C3_GALLBLADDER_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
229 |
4. Check minimum number of eventsNone |
229 |
5. Include endpointsNone |
229 |
6. Filter based on genotype QC (FinnGen only) |
229 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of gallbladder, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of digestive organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 229 | 141 | 88 |
| Unadjusted period prevalence (%) | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | 69.93 | 69.32 | 70.91 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 138
- Matched controls
- 1379
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C23
ICD-10 Finland
Malignant neoplasm of gallbladder
+∞
162.4
122
*
8140/3-C23.9
ICD-O-3
Adenocarcinoma, NOS, of gallbladder
+∞
107.9
89
*
130
Kela drug reimbursment
Malignant tumour
+∞
78.9
68
*
H02AB02
ATC
dexamethasone; systemic
308.9
44.8
43
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
41.8
38
*
A03FA01
ATC
metoclopramide; systemic, rectal
17.0
40.6
72
83
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
38.3
35
*
L01BC06
ATC
capecitabine; oral
+∞
36.0
33
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
58.9
27.9
32
7
JKA20
NOMESCO Finland
Cholecystectomy
49.3
26.2
31
8
Z51.5
ICD-10 Finland
Palliative care
28.8
26.0
35
16
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
24.7
23
*
8000/3-C23.9
ICD-O-3
Neoplasm, malignant of gallbladder
+∞
24.7
23
*
D37.6
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Liver, gallbladder and bile ducts
106.0
24.6
26
*
N02AA05
ATC
oxycodone; systemic
8.8
23.8
58
105
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
22.5
21
*
UJK02
NOMESCO Finland
ERCP
26.6
20.5
28
13
JN4CD
NOMESCO Finland
Very extensive body CT
54.7
19.9
23
5
JKE98
NOMESCO Finland
Other transduodenal endoscopic operation on bile duct or ampulla of Vater
45.5
19.2
23
6
K83.0
ICD-10 Finland
Cholangitis
40.8
17.2
21
6
JJB30
NOMESCO Finland
Excision of two segments of liver
+∞
17.0
16
*
JN4BD
NOMESCO Finland
Extensive body CT
10.9
16.4
32
37
JKA21
NOMESCO Finland
Laparoscopic cholecystectomy
7.3
15.9
41
75
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
15.9
15
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
5.4
15.7
55
150
JL5SB
NOMESCO Finland
Endoscopic retrograd cholangiopancreaticography
64.1
15.2
17
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
8.9
14.6
32
45
K83.1
ICD-10 Finland
Obstruction of bile duct
48.1
14.5
17
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
13.6
14.0
24
21
JKE18
NOMESCO Finland
Endoscopic internal drainage of bile duct
83.3
13.9
15
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
13.8
13
*
JKE02
NOMESCO Finland
Transduodenal endoscopic incision of common bile duct orifice
22.7
12.8
18
9
JK3BT
NOMESCO Finland
Catherisation of bile duct with X-ray guidance
+∞
12.7
12
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
10.9
12.6
24
26
A04AA01
ATC
ondansetron; systemic, rectal
20.5
12.4
18
10
K80.2
ICD-10 Finland
Calculus of gallbladder without cholecystitis
5.6
12.0
37
84
JN3BD
NOMESCO Finland
Extensive abdominal CT
6.9
11.8
30
53
WX408
NOMESCO Finland
General anesthesy, balanced
4.3
11.6
50
161
C24.9
ICD-10 Finland
Malignant neoplasm: Biliary tract, unspecified
+∞
11.6
11
*
JN4AD
NOMESCO Finland
Body CT examination
12.0
10.7
19
18
JJB10
NOMESCO Finland
Atypcal resection of liver
+∞
10.5
10
*
JK3NB
NOMESCO Finland
Percutaneous transhepatic cholangiography
+∞
10.5
10
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
10.5
10
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
10.4
10.4
20
22
K80.0
ICD-10 Finland
Calculus of gallbladder with acute cholecystitis
9.0
10.1
21
27
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
22.0
10.0
14
7
WZC30
NOMESCO Finland
Teaching
6.2
9.5
26
50
JAH00
NOMESCO Finland
Laparotomy
20.3
9.1
13
7
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
26.1
9.1
12
5
A04AA55
ATC
palonosetron, combinations; systemic
+∞
8.4
8
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
8.4
8
*
C78.6
ICD-10 Finland
Secondary malignant neoplasm of retroperitoneum and peritoneum
+∞
8.4
8
*
C22.9
ICD-10 Finland
Malignant neoplasm: Liver, unspecified
+∞
8.4
8
*
C22.1
ICD-10 Finland
Malignant neoplasm: Intrahepatic bile duct carcinoma
+∞
8.4
8
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.3
7.9
30
84
R17
ICD-10 Finland
Hyperbilirubinaemia, with or without jaundice, not elsewhere classified
47.7
7.8
9
*
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
19.7
7.7
11
6
D77
ICPC
Malignant digestive neopl other/NOS
+∞
7.4
7
*
JK3FT
NOMESCO Finland
Exchange of bile duct catheter with radiological guidance
+∞
7.4
7
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
7.4
7
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
7.4
7
*
D37.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other digestive organs
21.4
7.2
10
5
XX3DW
NOMESCO Finland
Time consuming IT work
7.4
7.1
16
24
WX402
NOMESCO Finland
General anaesthesia
4.3
6.8
25
67
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
23.9
6.8
9
*
K80.5
ICD-10 Finland
Calculus of bile duct without cholangitis or cholecystitis
7.5
6.7
15
22
JL5BG
NOMESCO Finland
MRI examinaiton of bile and pancreas ducts with high intesity magnet
13.1
6.7
11
9
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
8.8
6.5
13
16
K82.9
ICD-10 Finland
Disease of gallbladder, unspecified
73.1
6.5
7
*
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
+∞
6.3
6
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
6.3
6
*
JKE12
NOMESCO Finland
Endoscopic extraction of calculus from bile duct
13.3
6.2
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
123
101
25.15
135.80
7.0
1.4
14.9
5.4
ug/l
0.94
117
84
75
41
26.71
98.54
7.0
1.7
1498.2
171.3
u/ml
1.20
70
33
57
17
44.31
92.03
3.3
1.5
641.0
220.4
u/ml
0.27
57
17
66
120
7.32
37.22
3.7
1.8
0.2
0.2
g/l
0.56
66
104
77
166
6.48
36.63
8.0
1.8
22.9
6.5
umol/l
1.78
72
140
52
128
4.96
20.49
6.5
5.8
6.1
10.6
mmol/l
5.56
52
120
149
842
3.20
15.93
24.4
3.4
19.0
11.7
umol/l
1.38
149
784
120
697
2.52
10.67
5.4
3.4
—
—
—
0
0
74
347
2.67
10.22
2.6
1.9
—
—
—
0
0
35
117
3.35
8.76
1.4
1.4
1.4
1.6
%
0.90
30
100
132
1721
0.45
7.80
5.1
5.5
2.7
2.7
mmol/l
0.05
117
1556
127
1672
0.46
7.49
4.9
4.8
4.7
4.6
mmol/l
0.48
115
1523
126
1659
0.47
7.31
4.7
4.8
1.5
1.5
mmol/l
0.19
114
1503
131
1697
0.47
7.15
4.7
4.9
6.3
6.1
mmol/l
0.55
124
1526
14
29
5.08
6.54
1.3
1.4
—
—
—
0
0
124
1618
0.49
6.43
6.2
6.4
42.2
40.7
mmol/mol
0.68
111
1492
131
910
2.03
6.35
21.4
5.5
4.1
4.3
e9/l
0.58
124
781
123
1599
0.50
6.07
4.5
4.3
1.3
1.3
mmol/l
0.69
111
1433
45
212
2.40
5.89
2.3
2.4
23.8
22.0
%
0.33
40
186
27
110
2.65
4.75
2.0
1.6
—
—
—
0
0
10
21
4.93
4.57
1.4
1.1
—
—
—
0
0
158
1851
0.53
4.50
49.2
19.5
123.1
134.0
g/l
14.81
158
1815
118
858
1.77
4.37
7.3
4.9
1.2
1.2
mmol/l
4.26
101
740
8
10
8.24
4.09
2.4
1.0
—
—
—
0
0
39
202
2.12
4.03
5.7
5.6
1.1
1.6
mmol/l
0.48
31
162
46
254
2.01
4.02
2.5
2.2
13.1
12.6
umol/l
0.18
46
226
129
1576
0.58
3.80
4.6
5.0
2.0
2.0
mu/l
0.22
119
1418
10
26
3.98
3.56
1.5
2.7
60.3
61.2
%
—
10
26
6
7
8.76
3.28
4.7
1.4
2.8
5.8
nmol/l
—
6
7
17
67
2.66
3.21
1.8
1.6
0.8
2.0
ug/l
0.95
17
56
26
481
0.48
3.15
1.8
1.6
1.3
1.3
mmol/l
0.12
20
402
156
1790
0.60
3.13
42.3
15.7
73.6
78.2
umol/l
1.64
156
1790
25
120
2.22
3.12
5.2
2.8
1.2
1.2
mmol/l
0.09
25
97
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
50
2.70
2.58
1.6
2.3
0.4
0.4
u/ml
—
7
28
14
302
0.43
2.54
1.1
1.3
47.7
41.4
iu/ml
—
9
100
158
1784
0.63
2.53
29.8
9.1
33.1
24.1
u/l
5.31
158
1707
43
272
1.72
2.43
1.6
1.7
—
—
—
0
0
18
85
2.21
2.36
5.5
5.3
25.0
25.4
mmol/l
0.31
18
85
109
1306
0.68
2.12
3.6
4.1
15.3
15.0
pmol/l
0.35
97
1173
0
55
0.00
2.10
0.0
1.2
—
4.0
—
0
9
5
10
5.08
2.08
1.6
1.8
—
—
—
0
0
125
1452
0.69
1.98
32.0
14.7
35.8
39.5
%
3.19
83
941
19
99
2.00
1.97
6.6
6.8
0.7
0.7
%
0.02
19
99
19
99
2.00
1.97
6.2
6.8
1.4
1.4
%
0.08
19
99
15
283
0.50
1.89
1.1
1.3
1.3
14.0
u/ml
—
5
98
11
46
2.46
1.88
1.3
1.2
—
—
—
0
0
78
612
1.42
1.66
2.8
3.0
—
—
—
0
0
27
171
1.66
1.54
5.1
3.0
—
—
—
0
0
0
45
0.00
1.51
0.0
1.1
—
—
—
0
0
25
157
1.66
1.48
6.0
4.7
2.0
1.4
mmol/l
0.35
25
151
6
22
2.77
1.44
1.3
1.4
—
—
—
0
0
9
40
2.30
1.42
1.2
1.3
—
—
—
0
0
9
40
2.30
1.42
1.2
1.3
—
—
—
0
0
39
276
1.50
1.41
12.6
23.3
1.2
1.3
inr
—
8
42
142
1573
0.74
1.34
32.5
12.3
78.7
73.6
ml/min/173m2
2.23
132
1248
61
477
1.38
1.30
2.3
2.9
0.6
0.6
e6/l
0.11
48
343
112
1280
0.76
1.30
4.2
4.3
19.8
13.4
mm/h
2.71
106
1161
29
197
1.54
1.27
1.4
1.8
—
—
—
0
0
29
198
1.53
1.24
1.4
1.7
—
—
—
0
0
8
37
2.20
1.22
1.1
1.1
—
—
—
0
0
15
87
1.77
1.18
7.1
6.5
24.0
24.9
mmol/l
0.99
15
80
7
32
2.22
1.09
1.1
1.2
—
—
—
0
0
36
265
1.43
1.09
1.5
1.7
30.8
29.2
s
0.84
36
254
57
456
1.33
1.05
4.7
4.1
0.0
0.0
estimate
0.00
25
133
5
23
2.20
0.98
1.2
1.3
92.8
75.8
pmol/l
—
5
23
36
458
0.75
0.85
4.5
3.7
2.4
2.1
ug/l
0.25
29
405
15
97
1.58
0.83
3.0
3.8
5.0
5.2
kpa
0.55
15
88
8
48
1.69
0.79
1.9
1.5
—
—
—
0
0
69
801
0.80
0.79
2.1
2.0
96.2
93.8
pmol/l
0.18
44
370
14
91
1.57
0.77
3.1
3.7
2.0
2.3
mmol/l
—
8
66
86
753
1.23
0.76
4.0
4.0
43.9
80.0
ng/l
0.33
71
550
18
251
0.69
0.74
2.2
2.5
1.0
0.8
ug/l
0.65
11
171
11
68
1.65
0.73
1.5
1.5
—
—
—
0
0
71
813
0.82
0.70
2.0
2.4
—
—
—
0
0
5
28
1.80
0.66
1.2
1.1
—
—
—
0
0
10
62
1.64
0.66
1.3
1.4
—
—
—
0
0
6
101
0.58
0.63
3.8
2.1
1.0
1.2
%
—
6
101
19
139
1.40
0.63
2.2
1.4
67.0
66.8
g/l
0.03
19
120
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.1
—
7.5
—
0
16
74
658
1.18
0.54
4.3
4.1
—
—
—
0
0
81
728
1.17
0.52
1.9
2.2
79.9
80.0
nmol/l
0.01
76
632
29
353
0.80
0.51
1.2
1.3
0.6
1.9
u/ml
—
7
95
7
46
1.54
0.48
3.3
3.5
—
—
—
0
0
17
220
0.75
0.47
15.5
7.4
—
—
—
0
0
5
33
1.53
0.41
1.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.6
—
322.0
—
0
5
7
98
0.71
0.31
1.0
1.2
—
104.2
iu/ml
—
0
33
69
637
1.12
0.30
2.2
2.8
840.2
1634.3
ng/l
2.44
63
531
18
212
0.84
0.25
1.7
1.4
—
—
—
0
0
16
133
1.22
0.25
5.2
1.9
68.1
58.0
ml/min/173m2
—
10
50
22
190
1.17
0.24
1.1
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
770.4
—
0
11
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
1.1
—
0
7
0
12
0.00
0.21
0.0
2.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
26.8
—
0
5
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
46
425
1.10
0.20
1.7
1.7
493.5
462.3
pmol/l
0.31
40
342
30
270
1.13
0.20
2.0
2.8
5.9
3.5
e6/l
0.32
15
140
33
363
0.89
0.20
3.3
3.4
23.6
24.6
%
0.16
14
177
7
59
1.19
0.18
1.3
1.2
—
—
—
0
0
7
59
1.19
0.18
1.3
1.2
—
—
—
0
0
8
70
1.15
0.16
1.4
1.4
—
—
—
0
0
13
149
0.86
0.14
3.8
2.5
4.2
4.3
kpa
0.02
13
143
35
375
0.92
0.13
1.4
1.7
2.2
1.2
mg/l
0.69
26
292
5
61
0.82
0.08
1.2
1.1
34.7
38.1
g/l
—
5
50
5
63
0.79
0.08
1.2
1.4
—
—
—
0
0
6
73
0.82
0.07
1.3
2.0
35.3
41.0
u/l
—
6
62
8
75
1.07
0.07
1.1
1.2
—
—
—
0
0
40
411
0.97
0.03
4.5
4.2
1.0
1.0
kg/l
0.38
13
70
87
858
1.02
0.03
4.2
3.9
0.0
0.0
estimate
0.00
26
137
28
289
0.96
0.02
2.0
2.6
2.0
1.1
e6/l
0.39
13
156
12
113
1.07
0.02
1.8
1.4
—
—
—
0
0
85
842
1.02
0.01
4.1
3.9
0.0
0.0
estimate
0.00
27
138
11
109
1.01
0.00
1.5
1.7
—
—
—
0
0
85
849
1.00
0.00
4.9
5.2
0.0
0.0
estimate
0.00
26
135
40
395
1.02
0.00
4.3
4.1
229.4
242.2
ng/l
0.03
30
343
40
395
1.02
0.00
1.7
1.8
1216.4
1201.6
nmol/l
0.03
32
300
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
5
53
0.94
0.00
1.2
1.1
0.0
0.0
g/l
—
5
48
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
5
55
0.91
0.00
1.2
1.2
0.0
0.0
g/l
—
5
50
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1612.8
—
0
6
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
10.2
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
109.2
—
0
6
7
76
0.92
0.00
1.9
2.2
13.4
16.2
nmol/l
—
7
70
5
59
0.84
0.00
1.2
1.2
0.0
0.1
g/l
—
5
51
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_GALLBLADDER_EXALLC – Malignant neoplasm of gallbladder, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).